A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and four million HIV-negative people in the country would need to use the jab ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Argenx ...

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

A FDA generic drug office was eliminated — and the implications will be felt not only by drugmakers, but consumers ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...